Our Treatment

Engineering Plasma Physics
to Fight Cancer…

Our research team (JCRI-ABTS) at Canady Life Sciences is using
Cold Atmospheric Plasma to selectively Target Cancer Cells and
Disrupt the Cell’s ability to Reproduce and Survive

What is Canady HeliosTM Cold Plasma?

Canady Helios Cold Plasma (CHCP) is a non-thermal process that according to JCRI/ABTS Research, triggers chemical-molecular changes in cancer cells leading to apoptosis (cell death), while normal cells are left unharmed.

The Cold Plasma Beam introduces electronically charged particles, Reactive Oxygen Species (ROS) and Reactive Nitrogen Species (RNS) to the Plasma Treatment Electrical Field (PTEF).

A Multi-Disciplinary Treatment Process

A Typical Treatment Process

1. Pre-Operative Phase:
Patient Diagnosed with Soild Tumor

2. Pre-Operative Phase:
Standard Treatment Protocol - Radiation and/or Chemotherapy

3A - Intra-Operative Phase:
Removal of Tumor

3B - Intra-Operative Phase:
Application of Canady Helios Cold Plasma

4. Post-Operative Follow-up:
Chemotherapy (3-5 +/- Cycles)

The Canady Cold Plasma Helios Flexible EndoProbe™

The Next Generation of Endo-Oncology Surgery

Procedure for Endoscopic Mucosal Resection Secondary to Esophageal Cancer

STEP 1
Relieve acute obstruction with Canady Hybrid Plasma™

STEP 2
Place stent, if indicated

STEP 3
Ablate remaining tumor with Canady Hybrid Plasma™

STEP 4
Remove stent and ablate remaining soft tissue with Canady Helios™ Cold Plasma

STEP 5
Multi-Disciplinary Treatment Follow-up Process (Chemo/Radiation)

The Canady Cold Plasma Helios Flexible EndoProbe™

The Next Generation of Endo-Oncology Surgery

Procedure for Endoscopic Mucosal Resection Secondary to Esophageal Cancer

STEP 2
Relieve acute obstruction with Canady Hybrid Plasma™

STEP 3
Ablate remaining tumor with Canady Hybrid Plasma™

STEP 5
Multi-Disciplinary Treatment Follow-up Process (Chemo/Radiation)

STEP 1
Place stent, if indicated

STEP 4
Remove stent and ablate remaining soft tissue with Canady Helios™ Cold Plasma

The Canady Cold Plasma Helios Flexible EndoProbe™

The Next Generation of Endo-Oncology Surgery

Procedure for Endoscopic Mucosal Resection Secondary to Esophageal Cancer

STEP 1
Relieve acute obstruction with Canady Hybrid Plasma™

STEP 2
Place stent, if indicated

STEP 3
Ablate remaining tumor with Canady Hybrid Plasma™

STEP 4
Remove stent and ablate remaining soft tissue with Canady Helios™ Cold Plasma

STEP 5
Multi-Disciplinary Treatment Follow-up Process (Chemo/Radiation)

Safe – No Side Effects

The pioneering JCRI/ABTS Research proves when used intraoperatively (during your surgery), this low-temperature plasma treatment selectively targets cancer cells without damaging healthy surrounding tissue.

There is no hair loss or other side effects.

CHCP may be very effective
in treating Solid Tumor Cancers

Spraying CHCP in the surgical margins during your cancer surgery may reduce the chance of local recurrence and may improve your chance of survival (Based on JCRI/ABTS Research)

THE SCIENCE OF COLD PLASMA

The First Cold Atmospheric Plasma Phase I Clinical Trial for the Treatment of Advanced Solid Tumors: A Novel Treatment Arm for Cancer

Jerome Canady, Saravana R. K. Murthy, Taisen Zhuang, Steven Gitelis, Aviram Nissan, Lawan Ly, Olivia Z. Jones, Xiaoqian Cheng, Mohammad Adileh, Alan T. Blank, Matthew W. Colman, Kieth Millikan, Cristina O’Donoghue, Kerstin M. Stenson, Karen Ohara, Gal Schtrechman,...
Read More

Canady Cold Helios Plasma Reduces Soft Tissue Sarcoma Viability by Inhibiting Proliferation, Disrupting Cell Cycle, and Inducing Apoptosis: A Preliminary Report

Lawan Ly, Xiaoqian Cheng, Saravana R. K. Murthy, Olivia Z. Jones, Taisen Zhuang, Steven Gitelis, Alan T. Blank, Aviram Nissan, Mohammad Adileh, Matthew Colman, Michael Keidar, Giacomo Basadonna and Jerome Canady Soft tissue sarcomas (STS) are a rare and highly...
Read More

The Granger Causal Effects of Canady Helios Cold Plasma on the Inhibition of Breast Cancer Cell Proliferation

Annisa Elbedour, Xiaoqian Cheng, Saravana R. K. Murthy, Taisen Zhuang, Lawan Ly, Olivia Jones, Giacomo Basadonna, Michael Keidar, and Jerome CanadyCold atmospheric plasma (CAP) has become a promising tool for modern medicine. With its recent applications in oncology,...
Read More

BCL2A1 regulates Canady Helios Cold Plasma-induced cell death in triple-negative breast cancer

Saravana R. K. Murthy, Xiaoqian Cheng, Taisen Zhuang, Lawan Ly, Olivia Jones, Giacomo Basadonna, Michael Keidar, & Jerome CanadyBreast cancer is the most common cause of cancer death among women worldwide1 and it exhibits diverse molecular features that reflect the...
Read More

Canady Helios Cold Plasma Induces Breast Cancer Cell Death by Oxidation of Histone mRNA

Cold atmospheric plasma is a promising adjuvant therapy to selectively combat many cancers, including breast cancer, but not normal tissue; however, the underlying mechanisms remain unexplored. Here, four breast cancer cell lines with different marker status were treated with Canady Helios Cold Plasma™ (CHCP) at various dosages and their differential progress of apoptosis was monitored. Inhibition of cell proliferation, induction of apoptosis, and disruption of the cell cycle were observed. At least 16 histone mRNA types were oxidized and degraded immediately after CHCP treatment by 8-oxoguanine (8-oxoG) modification.

Read More